A Phase 2 Open-Label Single-Arm Study of Brentuximab Vedotin in Patients with CD30-Positive Nonlymphomatous Malignancies
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This study is being done to test whether brentuximab vedotin has an effect on cancer that is characterized by the CD30 antigen.
Description
This study is being done to test whether brentuximab vedotin has an effect on cancer that is characterized by the CD30 antigen.
Details
| Condition | CD30-Positive Nonlymphomatous Malignancies |
|---|---|
| Age | 6years - 100years |
| Clinical Study Identifier | TX2216 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.